CN101485861B - 具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂 - Google Patents
具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂 Download PDFInfo
- Publication number
- CN101485861B CN101485861B CN2009100679064A CN200910067906A CN101485861B CN 101485861 B CN101485861 B CN 101485861B CN 2009100679064 A CN2009100679064 A CN 2009100679064A CN 200910067906 A CN200910067906 A CN 200910067906A CN 101485861 B CN101485861 B CN 101485861B
- Authority
- CN
- China
- Prior art keywords
- liver
- pollen pini
- chinese medicine
- protecting
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 210000004369 blood Anatomy 0.000 title claims abstract description 14
- 239000008280 blood Substances 0.000 title claims abstract description 14
- 230000006870 function Effects 0.000 title abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 63
- 210000004185 liver Anatomy 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 30
- 239000000284 extract Substances 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 230000001681 protective effect Effects 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 15
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 12
- 239000000080 wetting agent Substances 0.000 claims description 9
- 230000001413 cellular effect Effects 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 230000001788 irregular Effects 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 239000007767 bonding agent Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 210000003494 hepatocyte Anatomy 0.000 abstract description 17
- 208000007848 Alcoholism Diseases 0.000 abstract description 11
- 201000007930 alcohol dependence Diseases 0.000 abstract description 11
- 230000006378 damage Effects 0.000 abstract description 7
- 206010067125 Liver injury Diseases 0.000 abstract description 5
- 230000003078 antioxidant effect Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 206010019233 Headaches Diseases 0.000 abstract description 4
- 230000008021 deposition Effects 0.000 abstract description 4
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 4
- 230000035622 drinking Effects 0.000 abstract description 4
- 229930195729 fatty acid Natural products 0.000 abstract description 4
- 239000000194 fatty acid Substances 0.000 abstract description 4
- 150000004665 fatty acids Chemical class 0.000 abstract description 4
- 231100000869 headache Toxicity 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 208000017667 Chronic Disease Diseases 0.000 abstract description 2
- 206010000059 abdominal discomfort Diseases 0.000 abstract description 2
- 201000006549 dyspepsia Diseases 0.000 abstract description 2
- 231100000234 hepatic damage Toxicity 0.000 abstract description 2
- 208000001286 intracranial vasospasm Diseases 0.000 abstract description 2
- 230000008818 liver damage Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 3
- 244000046146 Pueraria lobata Species 0.000 abstract 3
- 239000001702 nutmeg Substances 0.000 abstract 3
- 241000498779 Myristica Species 0.000 abstract 2
- 235000009421 Myristica fragrans Nutrition 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 235000013334 alcoholic beverage Nutrition 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 229940098295 nutmeg extract Drugs 0.000 abstract 1
- 230000005195 poor health Effects 0.000 abstract 1
- 230000003859 lipid peroxidation Effects 0.000 description 13
- 150000003254 radicals Chemical class 0.000 description 8
- 239000008187 granular material Substances 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 4
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 4
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010019837 Hepatocellular injury Diseases 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000003153 cholinolytic effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- -1 300 grams Substances 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 241001119522 Paullinia pinnata Species 0.000 description 1
- 235000010240 Paullinia pinnata Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000004385 Sulfurtransferases Human genes 0.000 description 1
- 108090000984 Sulfurtransferases Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂,其构成组分为松花粉20-80%;葛根提取物10-70%;肉豆蔻提取物5-50%;辅料5-30%。本发明是以纯天然食品松花粉、葛根、肉豆蔻为主要原料,经合理配方研制出的保健食品,专门针对经常饮酒的人群、身体肥胖的人群、三高病及慢性疾病患者,以保肝护肝、对抗酒精中毒引起的肝脏脂质过氧化损伤而达到对化学性肝损伤的保护作用;所含的松花粉含有丰富的抗氧化物质能减轻酒精对肝脏的脂质过氧化损伤,增强脂肪酸在肝细胞内代谢,减少脂肪在肝细胞内沉积、肉豆蔻具有调和脾胃功能,葛根还具有解除脑血管痉挛的作用,从而起到缓解酒后的头痛、胃部不适、消化不良及酒后身体虚弱等症状。
Description
技术领域
本发明属于中药组合物领域,尤其是一种具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂。
背景技术
松花粉、葛根、肉豆蔻的应用古已有之。《本草汇言》中记载松花粉能治酒毒、头痛方,药味配方:松花、陈皮、黄莲、甘草;功能主治:酒毒发作,头痛目眩,或咽喉闭闷,或下利清水,日数十行,行神萎顿。早在《神农本草经》中,就已记载葛根能“解诸毒”,此言“诸毒”,当涵盖有饮酒中毒;明确提出葛根解酒者,首推唐代甄权的《药性论》,说葛根能“开胃下食,解酒毒”;其后,陈藏器的《本 草拾遗》说,葛根“蒸食:消酒毒,可断谷不饥”;《开宝本草》亦载:“作粉:止渴,利大小便,解酒,去烦热”;《千金方》记载,饮鲜葛根汁可治“酒醉不醒”,治酒醉不醒,可用鲜葛根捣烂,榨汁,取300毫升饮之,能快速醒酒,且其性甘凉,能鼓舞胃气,对胃虚热渴,酒毒呕吐有效。肉豆蔻在《日华子本草》中就有“调中,下气,止泻痢,开胃,消食。解酒毒,治霍乱。”的记载;还在《本草正义》中写道:“肉豆蔻,除寒燥湿,解结行气,专理脾胃,大明谓温中下气,开胃解酒毒”。
现代药理学研究表明,乙醇进入人体内是先由ADH(醇脱氢酶)催化为乙醛,再经醛脱氢酶作用最终生成乙酸而解毒。在生理情况下80%的乙醇是被ADH代谢,余下的20%大部分由微粒体乙醇氧化系统代谢。有报道乙醇摄入后,使肝脏产生与醛类亲和力大的ADH2同工酶减少,致使乙醛在体内堆积,刺激脂质过氧化,导致乙醇中毒作用。服用葛根后科对抗乙醇对肝脏ADH活性减低的作用,有利于乙醇在体内的分解代谢,从而可以解酒毒。此外GST(谷光苷肽硫转移酶)是一组与肝脏功能有关的药物代谢酶,主要功能是催化谷光苷肽在体内的结合解毒,乙醇可使肝细胞内GST活性减低,从而导致机体解毒功能的降低。服用葛根后提高了肝细胞浆中GST活性水平,有利于机体解毒功能的发挥,保护肝细胞免受自由基、亲电子化合物和毒物的损害,从而可减轻乙醇的毒性。另外葛根总黄酮也具有解酒毒的作用,其作用机理可能与抗胆碱、解痉、增加脑及冠状血管血流量等作用有关。而葛根素可通过抑制β-EP(一种内源性阿片肽)的释放和抗自由基、减轻脂质过氧化、改善血液流变学等作用拮抗急性酒精中毒对神经系统和肝脏的损害作用,对酒精中毒有保护作用,可应用于临床治疗酒精中毒。
在正常的生理状态下机体通过自身的抗氧化酶系统,清除自由基,不至于引起组织细胞的脂质过氧化而出现肝损伤,在抗氧化酶系统中主要以SOD(超氧化物歧化酶)为代表,它具有消除自由基、阻止自由基的脂质过氧化作用。试验中肉豆蔻低、中、高剂量组的大鼠肝组织匀浆中的SOD活性检测高于损伤组,可认为其机制是提高SOD活性或其它抗氧化酶的活性,从而清除自由基,阻止肝细胞脂质过氧化,维持细胞质膜的正常结构,避免肝细胞的损伤。
刘协通过预先给予各组小鼠松花粉,剂量分别为500、1000mg/kg,30d后各剂量组及模型对照组小鼠经口一次给予乙醇4800mg/kg,建立急性肝损伤模型,观察松花粉对急性肝损伤小鼠肝脏脂质过氧化反应、肝细胞脂肪变性等的影响。结果:12h后各剂量组小鼠肝组织MDA(丙二醛)含量与乙醇模型组相比均降低,高剂量组具有显著差异(P<0.05);低、高剂量组肝组织GSH(谷光肝肽)含量均高于乙醇模型对照组,分别具有显著和极显著差异(P<0.05,P<0.01)。肝组织苏丹III染色显示,各剂量组肝细胞内脂滴比乙醇模型对照组明显减少。松花粉中含有丰富的维生素E、胡萝卜素,微量元素硒及黄酮等抗氧化物质,可抑制体内脂质过氧化反应。实验表明,预先给予松花粉则可显著抑制酒精导致的肝脏MDA含量增加,表明松花粉可对抗酒精所致的肝脏脂质过氧化反应,减轻酒精对肝细胞的损害。肝脏GSH含量变化显示,酒精可导致肝组织GSH的损耗,预先给予松花粉可阻抑肝组织GSH的含量下降。血清TG含量的变化及肝组织苏丹III染色显示,酒精可影响肝脏脂肪代谢,使血清TG含量升高,脂滴在肝细胞内沉积,预先给予松花粉可减轻酒精对脂肪代谢的影响。血清TG含量降低虽不明显,但肝细胞内脂滴明显减少,低剂量组肝细胞内仅见少许脂滴,高剂量组动物肝细胞内未见脂滴。实验结果表明松花粉对急性酒精性肝损伤有明显的保护作用,其作用机理可能与松花粉含有丰富的抗氧化物质,减轻酒精对肝脏的脂质过氧化损伤,增强脂肪酸在肝细胞内代谢,减少脂肪在肝细胞内沉积有关。
综上,将松花粉、葛根提取物、肉豆蔻提取物为主要原料,经过合理工艺制成解酒、降血脂并对肝脏、心脑血管具有保护作用的颗粒剂、胶囊剂、片剂产品。
发明内容
本发明目的在于选用经科学验证、普遍认可无毒无害的原料,经科学配伍制成的一种具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂。
本发明的目的是这样实现的:
一种具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂,其构成组分及重量百分比分别为:
松花粉 20-80%
葛根提取物 10-70%
肉豆蔻提取物 5-50%
辅料 5-30%。
而且,所述辅料为粘合剂及湿润剂,其中粘和剂为羧甲基淀粉钠,湿润剂为75%的食用酒精。
而且,所述松花粉为经超微粉碎的破壁松花粉,破壁后所形成的不规则碎片的粒径为7-15微米。
而且,所述葛根提取物的葛根素含量为20%以上。
而且,所述肉豆蔻提取物中的豆蔻提取率为18-20%。
一种具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂的制备方法,制备方法的步骤是:
(1)、将松花粉超微粉碎,所形成的不规则碎片的粒径为7-15微米;
(2)、将葛根提取物以及肉豆蔻提取物分别过50-70目筛,并与步骤(1)的超微破壁粉碎松花粉混合均匀;
(3)、加入粘合剂、湿润剂,混合均匀,在50-70℃干燥,即制成一种具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂成品。
本发明的优点和积极效果是:
1、本品是以纯天然食品松花粉、葛根、肉豆蔻为主要原料,经合理配方研制出的保健食品,专门针对经常饮酒的人群包括中、青年白领、中、老年人、身体肥胖的人群、三高病及慢性疾病患者,以保肝护肝、对抗酒精中毒引起的肝脏脂质过氧化损伤,而达到对化学性肝损伤的保护作用。本产品中所含的松花粉含有丰富的抗氧化物质,能减轻酒精对肝脏的脂质过氧化损伤,增强脂肪酸在肝细胞内代谢,减少脂肪在肝细胞内沉积、肉豆蔻具有调和脾胃功能,葛根还具有解除脑血管痉挛的作用,从而起到缓解酒后的头痛、胃部不适、消化不良及酒后身体虚弱等症状。
2、本产品的优势在于配方中松花粉含有丰富的维生素E、胡萝卜素,微量元素硒及黄酮等抗氧化物质,可抑制体内脂质过氧化反应,减轻酒精对肝脏的脂质过氧化损伤,增强脂肪酸在肝细胞内代谢,减少脂肪在肝细胞内沉积。而葛根中所含总黄酮有抗胆碱、解痉、增加脑及冠状血管血流量等作用。葛根素则可通过抑制β-EP的释放和抗自由基、减轻脂质过氧化、改善血液流变学,拮抗急性酒精中毒对神经系统和肝脏的损害作用。肉豆蔻可提高SOD活性或其它抗氧化酶的活性,清除自由基,阻止肝细胞脂质过氧化,维持细胞质膜的正常结构,避免肝细胞的损伤。上述原料中松花粉是作为普通食品管理的新资源食品,葛根和肉豆蔻是药食同源的天然植物产品,从古至今沿用已久,效果明显而无毒无害。
具体实施方式
以下对本发明的实施例做进一步详述,以下实施例只是描述性的,不是限定性的,不能以此限定本发明的保护范围。
一种具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂,其构成组分及重量百分比范围为:
松花粉 20-80%
葛根提取物 10-70%
肉豆蔻提取物 5-50%
辅料 5-30%。
本发明所指辅料为粘合剂和湿润剂,其中粘和剂为羧甲基淀粉钠,湿润剂为75%的食用酒精。
本发明的制备方法是(以制备1公斤本产品为例):
(1)、将440克松花粉超微粉碎,因天然松花粉颗粒有一层坚硬的外壳保护它的营养成分和遗传物质,超微粉碎将外壳打碎,颗粒成为碎片的过程称为破壁,经超微粉碎所形成的不规则碎片的粒径为7-15微米;
(2)、将420克葛根提取物(葛根素含量20%以上)以及100克的肉豆蔻提取物(提取率18-20%)分别过60目筛,并与步骤(1)的超微粉碎破壁松花粉混合均匀;
(3)、加入羧甲基淀粉钠(粘合剂)40克、75%食用酒精(湿润剂)300克,混合均匀,然后制粒,60℃干燥,即制成一种具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂颗粒剂成品;
(4)、上述将颗粒剂装入胶囊即可制成胶囊剂,将颗粒压片即可制成片剂。
Claims (2)
2.一种如权利要求1所述的具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂的制备方法,其特征在于:制备方法的步骤是:
(1)、将松花粉超微粉碎,所形成的不规则碎片的粒径为7-15微米;
(2)、将葛根提取物以及肉豆蔻提取物分别过50-70目筛,并与步骤(1)的超微粉碎破壁松花粉混合均匀;
(3)、加入粘合剂、湿润剂,混合均匀,在50-70℃干燥,即制成一种具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100679064A CN101485861B (zh) | 2009-02-23 | 2009-02-23 | 具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100679064A CN101485861B (zh) | 2009-02-23 | 2009-02-23 | 具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101485861A CN101485861A (zh) | 2009-07-22 |
CN101485861B true CN101485861B (zh) | 2011-09-07 |
Family
ID=40889022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100679064A Active CN101485861B (zh) | 2009-02-23 | 2009-02-23 | 具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101485861B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102641355B (zh) * | 2012-05-22 | 2014-01-15 | 楚雄医药高等专科学校 | 一种治疗高血脂症的酒制组方、保健酒及制备方法与应用 |
CN102934768B (zh) * | 2012-11-28 | 2014-07-09 | 江山福赐德蜂业科技开发有限公司 | 一种葛根素、松花粉和蜂胶复合片剂及其制备方法 |
CN102935108B (zh) * | 2012-11-30 | 2014-08-13 | 烟台新时代健康产业有限公司 | 用于解酒的松花粉水提取物肠溶片 |
CN102934808B (zh) * | 2012-11-30 | 2013-09-18 | 烟台新时代健康产业有限公司 | 用于解酒的松花粉水提取物口含片 |
CN102988429B (zh) * | 2013-01-10 | 2014-11-19 | 三门峡山水方正生物科技有限公司 | 一种防治酒精性肝损伤的松花粉片 |
CN103432248B (zh) * | 2013-08-21 | 2014-11-26 | 雷雨田 | 一种解酒护肝养胃保健品及其制备方法 |
CN106491709A (zh) * | 2016-12-30 | 2017-03-15 | 向关义 | 一种中药组合物及其制备方法与在制备降血脂的药物中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1799620A (zh) * | 2005-08-17 | 2006-07-12 | 王林祥 | 一种保健酒及其制备方法 |
-
2009
- 2009-02-23 CN CN2009100679064A patent/CN101485861B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1799620A (zh) * | 2005-08-17 | 2006-07-12 | 王林祥 | 一种保健酒及其制备方法 |
Non-Patent Citations (5)
Title |
---|
商亚珍.肉豆蔻提取物的生物学作用.《国外医学中医中药分册》.2001,第23卷(第1期),33. * |
未知.http://zhidao.baidu.com/quetion/37805744.《百度知道》.2007,1-2. * |
樊柏林等.破壁松花粉对高脂血症人群降血脂作用的观察.《职业与健康》.2006,第22卷(第22期),2012-2015. * |
苏军凯等.葛根治疗酒精中毒药理研究进展.《海峡药学》.2000,第12卷(第4期),1-4. * |
郭金英等.中草药解酒药物研究进展.《酿酒科技》.2007,(第11期),86-92. * |
Also Published As
Publication number | Publication date |
---|---|
CN101485861A (zh) | 2009-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101485861B (zh) | 具有解酒、降血脂并对肝脏、心脑血管具有保护作用的中药制剂 | |
CN102988638B (zh) | 一种青钱柳叶降脂降糖保健茶及其制备方法 | |
CN103861060B (zh) | 一种解酒片及其制备方法 | |
CN102178885B (zh) | 一种用于醒酒的药物组合物 | |
CN103203008A (zh) | 用于解酒的药物组合物及其制备方法 | |
CN108201138A (zh) | 一种解酒护肝组合物、组合物的制剂及其制备方法 | |
CN101284064A (zh) | 一种葛蓝降脂解酒药片的制备方法 | |
CN105362384B (zh) | 一种解酒醒酒的中药组合物及其应用 | |
CN102696830A (zh) | 一种弱碱性解酒护肝枳仙茶及其制备方法 | |
CN104082672A (zh) | 一种具有降血糖功效的养生粥及其制作方法 | |
CN105285260A (zh) | 一种解酒保健茶 | |
CN101745087A (zh) | 一种具有解酒防醉作用的组合物及其制备方法 | |
CN102342357A (zh) | 一种解酒异型糖片的配方及配制方法 | |
CN104171241A (zh) | 一种解酒口香糖 | |
CN104474472B (zh) | 具有降三高作用的苦丁茶含片及其生产方法 | |
CN107412665B (zh) | 一种具有解酒、防治酒精性肝损伤的中药组合物及其制备方法和应用 | |
CN103977206B (zh) | 改善肠胃消化系统功能的中药制剂及其生产方法 | |
CN105878812A (zh) | 以金花茶-石斛为原料的解酒饮料及其生产方法 | |
CN110973625A (zh) | 基于火麻仁的护肝醒酒组合物及其制备方法和应用 | |
CN101601814A (zh) | 一种治疗糖尿病的中药胶囊 | |
CN102132916A (zh) | 一种草本植物保健饮料 | |
CN104585469B (zh) | 一种对酒精性肝损伤具有保护作用的口香糖及其制备方法 | |
CN102416138A (zh) | 一种具有解酒降脂养胃作用的组合物及其制备方法 | |
CN103271402B (zh) | 一种降血糖功能性饮品 | |
CN105685912A (zh) | 一种柑橘百合润肺止咳蜂蜜 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |